Influenza in the COVID-19 era: principles of modern pharmacotherapy

Abstract

Influenza is one of the most common infectious diseases and a significant public health problem. Every year, the influenza virus causes 3–5 million severe cases, millions hospitalizations and approximately 650,000 deaths. According to WHO four new influenza strains are projected to circulate in the 2020–2021 epidemic season. Influenza A and B strains are: A/Guangdong-Maonan/ SWL1536/2019 (H1N1) pdm09, A/Hong Kong/2671/2019 (H3N2), B/Washington/02/2019 (Victoria lineage), B/ Phuket/3073/2013 (Yamagata lineage). In this context, the problem of prescribing rational antiviral therapy is particularly importance. COVID-19, along with influenza, is a group of respiratory viral infections, but important differences exist in terms of viral agents and the spread of infection. Important differences include the rate of transmission. The average incubation period and generation time (the time between infecting one person and infecting another) for influenza are shorter. COVID-19 may be more severe, causing complications and deaths in 3–4% of cases. The estimated generation time for COVID 19 is 5-6 days, while for influenza it is 3 days. According to the latest data, the reproductive number, i.e., the number of people who can be infected by one patient, is in the range of 2 to 2.5 in COVID 19, which is higher than in influenza. Only a laboratory test can accurately identify the type of pathogen and distinguish it from influenza and other respiratory viruses. Neuraminidase inhibitors are currently first-line drugs recommended by WHO for the treatment and prevention of influenza.